Bob, it's just my belief that regardless of how much detail they provide in a TLD statements there are shorts who'll try to attack anything that's said without substantiation. If a Journal paper is published simultaneously, or shortly after TLD, the details will be available. Shorts will be proven to be lying if the journal states the opposite of what the shorts are alleging.
Personally at this point I believe being short is foolish, yet I've been told that even penny stocks have people shorting, essentially hoping they'll go out of business.
I'm certainly of the belief that DCVax-L will be approved without further trials, but if I were wrong, I believe the worst case would be a small trial with a patient group where DCVax-L has been shown to be most effective. Certainly the share price would be down, but it would be temporary. I don't believe it will happen, overall results are just too good, but I never can be certain about the FDA. If there should be a delay, I'd be willing to bet that we'll gain European approval without any further delay, and that alone should take the stock higher than it is now.
It's clear that we have people who're either on the short side, or at least attempting to keep the price down so they can acquire more, or someone they work with can. I've always heard their are people who can be hired create doubt who aren't investors at all, I don't know what's the case here, or why but once the TLD and peer review has occurred, I don't believe they can hold the stock down. Thing is, if they've loaded up with shares, they could go the other way and take the up side until they were certain the price was well over what it should be, then go short again. As small investors we're at the mercy of such manipulators over short term rises and falls, but if we're right in the long run, we'll do very well.
Gary
Market Data 
Markets 
AI
